Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

Hagop Kantarjian, Charles Sawyers, Andreas Hochhaus, Francois Guilhot, Charles Schiffer, Carlo Gambacorti-Passerini, Dietger Niederwieser, Debra Resta, Renaud Capdeville, Ulrike Zoellner, Moshe Talpaz, Brian Druker

Research output: Contribution to journalArticle

1706 Citations (Scopus)

Abstract

Background. Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase. Methods. A total of 532 patients with late-chronicphase CML in whom previous therapy with interferon alfa had failed were treated with 400 mg of oral imatinib daily. Patients were evaluated for cytogenetic and hematologic responses. Time to progression, survival, and toxic effects were also evaluated. Results. Imatinib induced major cytogenetic responses in 60 percent of the 454 patients with confirmed chronic-phase CML and complete hematologic responses in 95 percent. After a median follow-up of 18 months, CML had not progressed to the accelerated or blast phases in an estimated 89 percent of patients, and 95 percent of the patients were alive. Grade 3 or 4 nonhematologic toxic effects were infrequent, and hematologic toxic effects were manageable. Only 2 percent of patients discontinued treatment because of drug-related adverse events, and no treatment-related deaths occurred. Conclusions. Imatinib induced high rates of cytogenetic and hematologic responses in patients with chronic-phase CML in whom previous interferon therapy had failed.

Original languageEnglish (US)
Pages (from-to)645-652
Number of pages8
JournalNew England Journal of Medicine
Volume346
Issue number9
DOIs
StatePublished - Feb 28 2002
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetics
Poisons
Leukemia, Myeloid, Chronic Phase
Blast Crisis
Philadelphia Chromosome
Therapeutics
Imatinib Mesylate
Drug-Related Side Effects and Adverse Reactions
Interferon-alpha
Protein-Tyrosine Kinases
Interferons
Phosphotransferases
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., ... Druker, B. (2002). Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. New England Journal of Medicine, 346(9), 645-652. https://doi.org/10.1056/NEJMoa011573

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. / Kantarjian, Hagop; Sawyers, Charles; Hochhaus, Andreas; Guilhot, Francois; Schiffer, Charles; Gambacorti-Passerini, Carlo; Niederwieser, Dietger; Resta, Debra; Capdeville, Renaud; Zoellner, Ulrike; Talpaz, Moshe; Druker, Brian.

In: New England Journal of Medicine, Vol. 346, No. 9, 28.02.2002, p. 645-652.

Research output: Contribution to journalArticle

Kantarjian, H, Sawyers, C, Hochhaus, A, Guilhot, F, Schiffer, C, Gambacorti-Passerini, C, Niederwieser, D, Resta, D, Capdeville, R, Zoellner, U, Talpaz, M & Druker, B 2002, 'Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia', New England Journal of Medicine, vol. 346, no. 9, pp. 645-652. https://doi.org/10.1056/NEJMoa011573
Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. New England Journal of Medicine. 2002 Feb 28;346(9):645-652. https://doi.org/10.1056/NEJMoa011573
Kantarjian, Hagop ; Sawyers, Charles ; Hochhaus, Andreas ; Guilhot, Francois ; Schiffer, Charles ; Gambacorti-Passerini, Carlo ; Niederwieser, Dietger ; Resta, Debra ; Capdeville, Renaud ; Zoellner, Ulrike ; Talpaz, Moshe ; Druker, Brian. / Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. In: New England Journal of Medicine. 2002 ; Vol. 346, No. 9. pp. 645-652.
@article{0ddd226536bc4770a59c6b4a12ea3ad6,
title = "Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia",
abstract = "Background. Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase. Methods. A total of 532 patients with late-chronicphase CML in whom previous therapy with interferon alfa had failed were treated with 400 mg of oral imatinib daily. Patients were evaluated for cytogenetic and hematologic responses. Time to progression, survival, and toxic effects were also evaluated. Results. Imatinib induced major cytogenetic responses in 60 percent of the 454 patients with confirmed chronic-phase CML and complete hematologic responses in 95 percent. After a median follow-up of 18 months, CML had not progressed to the accelerated or blast phases in an estimated 89 percent of patients, and 95 percent of the patients were alive. Grade 3 or 4 nonhematologic toxic effects were infrequent, and hematologic toxic effects were manageable. Only 2 percent of patients discontinued treatment because of drug-related adverse events, and no treatment-related deaths occurred. Conclusions. Imatinib induced high rates of cytogenetic and hematologic responses in patients with chronic-phase CML in whom previous interferon therapy had failed.",
author = "Hagop Kantarjian and Charles Sawyers and Andreas Hochhaus and Francois Guilhot and Charles Schiffer and Carlo Gambacorti-Passerini and Dietger Niederwieser and Debra Resta and Renaud Capdeville and Ulrike Zoellner and Moshe Talpaz and Brian Druker",
year = "2002",
month = "2",
day = "28",
doi = "10.1056/NEJMoa011573",
language = "English (US)",
volume = "346",
pages = "645--652",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "9",

}

TY - JOUR

T1 - Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

AU - Kantarjian, Hagop

AU - Sawyers, Charles

AU - Hochhaus, Andreas

AU - Guilhot, Francois

AU - Schiffer, Charles

AU - Gambacorti-Passerini, Carlo

AU - Niederwieser, Dietger

AU - Resta, Debra

AU - Capdeville, Renaud

AU - Zoellner, Ulrike

AU - Talpaz, Moshe

AU - Druker, Brian

PY - 2002/2/28

Y1 - 2002/2/28

N2 - Background. Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase. Methods. A total of 532 patients with late-chronicphase CML in whom previous therapy with interferon alfa had failed were treated with 400 mg of oral imatinib daily. Patients were evaluated for cytogenetic and hematologic responses. Time to progression, survival, and toxic effects were also evaluated. Results. Imatinib induced major cytogenetic responses in 60 percent of the 454 patients with confirmed chronic-phase CML and complete hematologic responses in 95 percent. After a median follow-up of 18 months, CML had not progressed to the accelerated or blast phases in an estimated 89 percent of patients, and 95 percent of the patients were alive. Grade 3 or 4 nonhematologic toxic effects were infrequent, and hematologic toxic effects were manageable. Only 2 percent of patients discontinued treatment because of drug-related adverse events, and no treatment-related deaths occurred. Conclusions. Imatinib induced high rates of cytogenetic and hematologic responses in patients with chronic-phase CML in whom previous interferon therapy had failed.

AB - Background. Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase. Methods. A total of 532 patients with late-chronicphase CML in whom previous therapy with interferon alfa had failed were treated with 400 mg of oral imatinib daily. Patients were evaluated for cytogenetic and hematologic responses. Time to progression, survival, and toxic effects were also evaluated. Results. Imatinib induced major cytogenetic responses in 60 percent of the 454 patients with confirmed chronic-phase CML and complete hematologic responses in 95 percent. After a median follow-up of 18 months, CML had not progressed to the accelerated or blast phases in an estimated 89 percent of patients, and 95 percent of the patients were alive. Grade 3 or 4 nonhematologic toxic effects were infrequent, and hematologic toxic effects were manageable. Only 2 percent of patients discontinued treatment because of drug-related adverse events, and no treatment-related deaths occurred. Conclusions. Imatinib induced high rates of cytogenetic and hematologic responses in patients with chronic-phase CML in whom previous interferon therapy had failed.

UR - http://www.scopus.com/inward/record.url?scp=0037186915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037186915&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa011573

DO - 10.1056/NEJMoa011573

M3 - Article

C2 - 11870241

AN - SCOPUS:0037186915

VL - 346

SP - 645

EP - 652

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 9

ER -